Imidazo[1,2-a]pyridine compounds
    2.
    发明授权
    Imidazo[1,2-a]pyridine compounds 有权
    咪唑并[1,2-a]吡啶化合物

    公开(公告)号:US06613775B1

    公开(公告)日:2003-09-02

    申请号:US09403510

    申请日:1999-10-22

    IPC分类号: A61K31437

    CPC分类号: C07D471/04

    摘要: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及抑制外源性或内源性刺激的胃酸分泌的式(I)的新化合物及其治疗上可接受的盐,因此可用于预防和治疗胃肠炎性疾病。

    Compounds for inhibition of gastric acid secretion
    3.
    发明授权
    Compounds for inhibition of gastric acid secretion 失效
    用于抑制胃酸分泌的化合物

    公开(公告)号:US06265415B1

    公开(公告)日:2001-07-24

    申请号:US09043040

    申请日:1998-03-10

    IPC分类号: A61K31437

    CPC分类号: C07D471/04

    摘要: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及式(I)的咪唑并吡啶衍生物,其中苯基部分被2-和6-位的低级烷基取代,其抑制外源或内源性刺激的胃酸分泌,因此可用于预防 并治疗胃肠道炎症性疾病。

    Imidazopyridine derivatives which inhibit the secretion of gastric acid
    4.
    发明授权
    Imidazopyridine derivatives which inhibit the secretion of gastric acid 有权
    抑制胃酸分泌的咪唑并吡啶衍生物

    公开(公告)号:US08993589B2

    公开(公告)日:2015-03-31

    申请号:US14183852

    申请日:2014-02-19

    申请人: Mikael Dahlström

    发明人: Mikael Dahlström

    IPC分类号: A61K31/44 C07D471/04

    CPC分类号: C07D471/04

    摘要: The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及式I的取代的咪唑并[1,2-a]吡啶,其中R是-CH 2 COOH或-COOH,其抑制外源或内源性刺激的胃酸分泌,并且可用于预防和治疗胃酸相关疾病 和胃肠道炎性疾病。

    IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID
    5.
    发明申请
    IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID 审中-公开
    抑制胃酸分泌的咪唑吡啶衍生物

    公开(公告)号:US20140235666A1

    公开(公告)日:2014-08-21

    申请号:US14183852

    申请日:2014-02-19

    申请人: Mikael DAHLSTRÖM

    发明人: Mikael DAHLSTRÖM

    IPC分类号: C07D471/04

    CPC分类号: C07D471/04

    摘要: The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及式I的取代的咪唑并[1,2-a]吡啶,其中R是-CH 2 COOH或-COOH,其抑制外源或内源性刺激的胃酸分泌,并且可用于预防和治疗胃酸相关疾病 和胃肠道炎性疾病。

    Salts of omeprazole and esomeprazole II
    7.
    发明授权
    Salts of omeprazole and esomeprazole II 失效
    奥美拉唑和埃索美拉唑盐

    公开(公告)号:US07560472B2

    公开(公告)日:2009-07-14

    申请号:US10569820

    申请日:2004-09-01

    IPC分类号: A61K31/4439 C07D401/12

    CPC分类号: C04B35/632 C07D401/12

    摘要: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.

    摘要翻译: 本发明涉及奥美拉唑的单一对映异构体的新盐,即(S)-5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] - ((S) - 奥美拉唑)和(R)-5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] -1H-苯并咪唑((R ) - 奥美拉唑)。 更具体地,本发明涉及通过(S) - 奥美拉唑和(R) - 奥美拉唑与1-环己基乙胺的反应形成的化合物的1-环己基乙基铵盐。 本发明还涉及通过施用本发明的化合物制备本发明化合物的方法,药物制剂和治疗胃相关疾病的方法。

    Salts of omeprazole and esomeprazole I
    8.
    发明授权
    Salts of omeprazole and esomeprazole I 失效
    奥美拉唑和埃索美拉唑盐

    公开(公告)号:US07326724B2

    公开(公告)日:2008-02-05

    申请号:US10569819

    申请日:2004-09-01

    IPC分类号: A61K31/4439 C07D401/12

    摘要: The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to adamantan ammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and adamantan amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.

    摘要翻译: 本发明分别涉及奥美拉唑和艾美拉唑的新盐,即5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] -1H-苯并咪唑的盐和 (S) - 对映体。 更具体地,本发明涉及通过奥美拉唑和埃索美拉唑与金刚烷胺的反应形成的化合物金刚烷铵盐。 本发明还涉及通过施用本发明的化合物制备本发明化合物的方法,药物制剂和治疗胃相关疾病的方法。

    Alkylammonium salts of omeprazole and esomeprazole
    9.
    发明授权
    Alkylammonium salts of omeprazole and esomeprazole 失效
    奥美拉唑和艾美拉唑的烷基铵盐

    公开(公告)号:US07345061B2

    公开(公告)日:2008-03-18

    申请号:US10506345

    申请日:2003-03-04

    申请人: Mikael Dahlström

    发明人: Mikael Dahlström

    IPC分类号: A61K31/4439 C07D401/12

    CPC分类号: C07D401/12 C04B35/632

    摘要: The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzirnidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salts of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR1R2R3, wherein R1 is a linear, branched, or cyclic C1-C12-alkyl group, and R2 and R3 are hydrogen. The present invention also relates to a process for preparing crystalline salts, a pharmaceutical preparation, and a method for treatment of gastric related disorders by administering the compound of the invention.

    摘要翻译: 本发明分别涉及奥美拉唑和艾美拉唑的新盐,即5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] -1H-苯并咪唑的盐和 (S) - 对映体。 更具体地,本发明涉及通过奥美拉唑和埃索美拉唑的反应形成的化合物的烷基铵盐和具有式NR 1 R 2 R 2的烷基胺, 其中R 1是直链,支链或环状的C 1 -C 12 - 烷基,R 1, SUB 2和R 3是氢。 本发明还涉及通过施用本发明的化合物制备结晶盐的方法,药物制剂和治疗胃相关疾病的方法。